血清转化
医学
临时的
乙型肝炎表面抗原
中期分析
慢性肝炎
内科学
胃肠病学
病毒学
乙型肝炎病毒
临床试验
病毒
历史
考古
作者
Guiqiang Wang,Yimin Chen,Youhua Xie,Qianguo Mao,Xie Quan,Yu Gu,Xinyue Chen,Guoxin Hu,Yue Yang,Jiajie Lu,Guizhou Zou,Qin Zhang,Lei Fu,Yongping Chen,Xiaolin Guo,Jinlin Hou,Yue-Mei Yan,Handan He,Jinzi J. Wu
标识
DOI:10.1016/s0168-8278(22)00538-4
摘要
ALT) levels throughout the study; 2 participants in each regimen had grade 1 ALT elevations.No treatment-related serious AEs were reported. Conclusion:These preliminary data support that a longer duration of treatment with VIR-2218 results in deeper and more sustained reductions in HBsAg.In both regimens of VIR-2218, no differences in safety or tolerability were observed.
科研通智能强力驱动
Strongly Powered by AbleSci AI